Merck announced that its PD-1 inhibitor pembrolizumab (trade name: Coretta) has been approved by China's State Drug Administration (NMPA) for the first-line treatment of unresectable or metastatic melanoma.。This approval changes the indication for melanoma in the product specification from "pembrolizumab for the treatment of unresectable or metastatic melanoma that has failed first-line therapy" to "pembrolizumab for the treatment of unresectable or metastatic melanoma."。(interface)
Merck announced that its PD-1 inhibitor pembrolizumab (trade name: Coretta) has been approved by China's State Drug Administration (NMPA) for the first-line treatment of unresectable or metastatic melanoma.。This approval changes the indication for melanoma in the product specification from "pembrolizumab for the treatment of unresectable or metastatic melanoma that has failed first-line therapy" to "pembrolizumab for the treatment of unresectable or metastatic melanoma."。(interface)
Disclaimer: The views in this article are from the original author and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.
